Compliance with quality of life data collection in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial

Statistics in Medicine

Volumn 17, Issue 5-7, 1998, Pages 613-622

  Ganz, Patricia A ^a   Day, Richard ^b   Costantino, Joseph ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; INFORMATION PROCESSING; PATIENT COMPLIANCE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SOCIOECONOMICS;

EID: 2642617784     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0258(19980315/15)17:5/7<613::aid-sim808>3.0.co;2-9     Document Type: Conference Paper

References (14)

1. Fisher, B., Costantino, J., Redmond, C., et al. 'A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors', New England Journal of Medcine, 320, 479-484 (1989).
2. Nolvadex Adjuvant Trial Organization. 'Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer', Lancet, 1, 836-839 (1985).
3. Breast Cancer Trials Committee, Scottish Cancer Trials Office. 'Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial', Lancet, 2, 171-175 (1987).
4. Early Breast Cancer Trialists' Collaborative Group. 'Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy', Lancet, 339, 1-15, 71-85 (1992).
5. Abram, W. P., Baum, M., Berstock, D. A., et al. 'Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Preliminary analysis by the CRC Adjuvant Breast Trial Working Party', British Journal of Cancer, 57, 604-607 (1988).
6. Fornander, T., Rutqvist, L. E., Cedermark, B., et al. 'Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers', Lancet, 1, 117-120 (1989).
7. Bertelli, G., Pronzato, P., Amoroso, D., et al. 'Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III level', Breast Cancer Research and Treatment, 12, 307-310 (1988).
8. Rossner, S. and Wallgren, A. 'Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen', Atherosclerosis, 52, 339-346 (1984).
9. Bruning, P. F., Bonfrer, J. M., Hart, A. A., et al. 'Tamoxifen, serum lipoproteins and cardiovascular risk', British Journal of Cancer, 58, 497-499 (1988).
10. Love, R. R., Newcomb, P. A., Wiebe, D. A., et al. 'Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer', Journal of the National Cancer Institute, 82, 1327-1332 (1990).
11. Bagdade, J. D., Wolter, J., Subbaiah, P. V. and Ryan, W. 'Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition', Journal of Clinical Endocrinology and Metabolism, 70, 1132-1135 (1990).
12. Rutqvist, L. E. and Mattson, A. (Stockholm Breast Cancer Study Group). 'Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen', Journal of the National Cancer Institute, 85, 1398-1406 (1993).
13. Ganz, P. A., Day, R., Ware, J. E. Jr, Redmond, C. and Fisher, B. 'Base-line Quality of Life Assessment in the national Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial', Journal of the National Cancer Institute, 87, 1371-1382 (1995).
14. Ganz, P. A., Haskell, C. M., Figlin, R., et al. 'Estimating the Quality of Life in a Clinical Trial of Metastatic Lung Cancer Using the Karnofsky Performance Status and the Functional Living Index-Cancer (FLIC)', Cancer, 61, 849-856 (1988).